← Back to Analyst Consensus 
IMNM Buy
Immunome Inc.
Current Price —
Implied Upside —
Analysts 22
30-Day Momentum
▲ 2 upgrades / ▼ 0 downgrades / 0 reiterations from 2 firms
Next Earnings
Nov 16, 2026 (21 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 16, 2026 | William Blair | initiate | — → Outperform | $0 | 48% |
| Oct 1, 2026 | Stifel | initiate | — → Hold | $24 | 53% |
| Sep 21, 2026 | Alliance Global Partners | initiate | — → Buy | $32 | 41% |
| Sep 10, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $40 | 44% |
| Aug 12, 2026 | Truist Securities | maintain | Buy → Buy | $38 | 54% |
| Aug 12, 2026 | Wedbush | maintain | Outperform → Outperform | $35 | 58% |
| Jul 21, 2026 | Wedbush | reiterate | Outperform → Outperform | $31 | 58% |
| Jun 12, 2026 | Wedbush | reiterate | Outperform → Outperform | $31 | 58% |
| May 28, 2026 | Truist Securities | maintain | Buy → Buy | $37 | 54% |
| May 28, 2026 | Barclays | initiate | — → Overweight | $36 | 53% |
| May 15, 2026 | Leerink Partners | maintain | Outperform → Outperform | $33 | 50% |
| May 13, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $40 | 44% |
| Mar 4, 2026 | Craig-Hallum | maintain | Buy → Buy | — | 54% |
| Mar 4, 2026 | Stephens & Co. | maintain | Overweight → Overweight | — | 54% |
| Feb 12, 2026 | HC Wainwright & Co. | initiate | — → Buy | $40 | 44% |
| Jan 15, 2026 | Wedbush | reiterate | Outperform → Outperform | $31 | 58% |
| Dec 16, 2025 | Lake Street | maintain | Buy → Buy | $32 | 47% |
| Dec 16, 2025 | Evercore ISI Group | maintain | Outperform → Outperform | $40 | 58% |
| Dec 16, 2025 | Guggenheim | maintain | Buy → Buy | $35 | 52% |
| Dec 1, 2025 | Truist Securities | initiate | — → Buy | $36 | 54% |
| Nov 17, 2025 | Stephens & Co. | maintain | Overweight → Overweight | $33 | 54% |
| Sep 22, 2025 | Goldman Sachs | initiate | — → Buy | $26 | 54% |
| Sep 5, 2025 | Craig-Hallum | initiate | — → Buy | $26 | 54% |
| Aug 25, 2025 | Guggenheim | reiterate | Buy → Buy | $25 | 52% |
| Aug 22, 2025 | Evercore ISI Group | initiate | — → Outperform | $18 | 58% |
| Aug 7, 2025 | JP Morgan | maintain | Overweight → Overweight | $22 | 55% |
| Apr 2, 2025 | Lake Street | initiate | — → Buy | $23 | 47% |
| Mar 20, 2025 | Wedbush | reiterate | Outperform → Outperform | $33 | 58% |
| Mar 20, 2025 | Stephens & Co. | reiterate | Overweight → Overweight | $30 | 54% |
| Mar 20, 2025 | Guggenheim | maintain | Buy → Buy | $25 | 52% |
| Mar 11, 2025 | LifeSci Capital | initiate | — → Outperform | $20 | 57% |
| Nov 14, 2024 | Piper Sandler | maintain | Overweight → Overweight | $21 | 54% |
| Nov 8, 2024 | Stephens & Co. | initiate | — → Overweight | $30 | 54% |
| Oct 25, 2024 | Wedbush | reiterate | Outperform → Outperform | $33 | 58% |
| Aug 13, 2024 | Wedbush | reiterate | Outperform → Outperform | $33 | 58% |
| Aug 13, 2024 | Piper Sandler | maintain | Overweight → Overweight | $23 | 54% |
| May 31, 2024 | Piper Sandler | initiate | — → Overweight | $27 | 54% |
| Apr 30, 2024 | JP Morgan | initiate | — → Overweight | $24 | 55% |
| Apr 15, 2024 | Guggenheim | initiate | — → Buy | $35 | 52% |
| Apr 1, 2024 | Wedbush | maintain | Outperform → Outperform | $33 | 58% |
| Jan 23, 2024 | Wedbush | maintain | Outperform → Outperform | $19 | 58% |
| Dec 19, 2023 | Wedbush | initiate | — → Outperform | $12 | 58% |
| Mar 20, 2023 | Cantor Fitzgerald | reiterate | — → Overweight | $8 | 50% |
| Mar 17, 2023 | Chardan Capital | maintain | — → Buy | $8 | 47% |
| Oct 29, 2021 | Cantor Fitzgerald | initiate | — → Overweight | $35 | 50% |
| Oct 27, 2020 | Chardan Capital | initiate | — → Buy | $18 | 47% |
Price Target Trend
Jun 10, 2026 Oct 25, 2026
EPS Estimates
0y —
+1y —
+1q —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days